GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week at the American Society of Clinical Oncology’s annual meeting. Subscribe to ...

The obesity and diabetes markets are on the cusp of transformation, driven by cutting-edge GLP-1 therapies. Eli Lilly and Novo Nordisk are shaping the competitive landscape, with novel drugs like ...

Taking weight-loss drugs means eating less—and for many Americans, dining out less, too. A growing body of research shows that people on GLP-1s are denting the restaurant business by cutting back on ...

Nike's business is struggling. The company's margins have been pressured by a combination of rising costs and weaker pricing power in a weaker-demand environment, driven by consumers' greater ...

Popular GLP-1 medications used for weight loss could help some people with sleep apnea. This is a fish that gets eaten alive and keeps swimming Dick Van Dyke, 99, names the two things to avoid to live ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. There have been many headlines in the last week about $50 weight-loss drugs for Medicare ...

A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term. Researchers say these ...

The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, ...

Chanel Robinson achieved exactly what the gold rush of blockbuster weight-loss drugs promised: She lost nearly 100 pounds, lowered her cholesterol to normal levels and reined in her polycystic ovary ...

If you purchase an independently reviewed product or service through a link on our website, SheKnows may receive an affiliate commission. Related story This $5 Foundation Is Beloved for Making Skin ...

Nike (NYSE: NKE) stock has been going through an extended rough patch. Sales and earnings have been under pressure, and industry dynamics have also called into question the extent of the company's ...

GLP-1 weight-loss drugs have generally been seen as bad news for restaurant chains — but maybe not for Cheesecake Factory, thanks in part to its gargantuan menu. J.P. Morgan analysts said in a note ...